Quantamental Biotech Investing

Biotech is entering an age of unprecedented growth and value creation. From small molecules to gene editing, Bender Capital is committed to investing in the bleeding edge of biotechnological advancement.

Through the unique combination of quantitative methods and fundamental insights, our firm aims to strategically invest in companies at their peak stage of return relative to their perceived risk profile. While biotech has historically been viewed as a speculative investment, our firm aims to disprove this perception by delivering superior risk-adjusted returns to our investors.